Peptide Library

In clinical trials

Brain & sleep

NNZ-2591

Evidence

Clinical trials

Class

Synthetic analog of cyclic glycine-proline

KEY TAKEAWAY

NNZ-2591 is a synthetic version of cyclic glycine-proline, a small molecule related to a breakdown product of IGF-1. It is being developed as an oral drug for rare neurodevelopmental disorders. NNZ-2591 is not FDA-approved and is still being tested in clinical trials.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

Synthetic analog of cyclic glycine-proline

Being studied for

Studied in rare neurodevelopmental conditions such as Phelan-McDermid and Angelman syndromes

Key fact

NNZ-2591 is not FDA-approved and is still being tested in clinical trials.

Route

Oral liquid in trials

Evidence strength

Clinical trials

What it is

What it is

NNZ-2591 is a synthetic version of cyclic glycine-proline, a small molecule related to a breakdown product of IGF-1. It is being developed as an oral drug for rare neurodevelopmental disorders.

How it works

How it works

It is thought to help regulate IGF-1 signaling and reduce inflammation in the brain, which may support healthy development of nerve connections.

Regulatory status

Regulatory status

NNZ-2591 is not FDA-approved and is still being tested in clinical trials.

What it is used for

What it is used for

Studied in rare neurodevelopmental conditions such as Phelan-McDermid and Angelman syndromes.

Side effects and risks

Side effects and risks

Early studies described it as generally well tolerated, but safety data are still limited.

Citations

Citations

NNZ-2591: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo